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Context: Primary adrenal insufficiency (PAI) is a life-threatening condition that is often due to
monogenic causes in children. Although congenital adrenal hyperplasia occurs commonly, several
other important molecular causes have been reported, often with overlapping clinical and bio-
chemical features. The relative prevalence of these conditions is not known, but making a specific
diagnosis can have important implications for management.
Objective: The objective of the study was to investigate the clinical and molecular genetic char-
acteristics of a nationwide cohort of children with PAI of unknown etiology.
Design: A structured questionnaire was used to evaluate clinical, biochemical, and imaging data.
Genetic analysis was performed using Haloplex capture and next-generation sequencing. Patients
with congenital adrenal hyperplasia, adrenoleukodystrophy, autoimmune adrenal insufficiency,
or obvious syndromic PAI were excluded.
Setting: The study was conducted in 19 tertiary pediatric endocrinology clinics.
Patients: Ninety-five children (48 females, aged 0–18 y, eight familial) with PAI of unknown eti-
ology participated in the study.
Results: A genetic diagnosis was obtained in 77 patients (81%). The range of etiologies was as
follows: MC2R (n  25), NR0B1 (n  12), STAR (n  11), CYP11A1 (n  9), MRAP (n  9), NNT (n 
7), ABCD1 (n  2), NR5A1 (n  1), and AAAS (n  1). Recurrent mutations occurred in several genes,
such as c.560delT in MC2R, p.R451W in CYP11A1, and c.IVS3ds1delG in MRAP. Several important
clinical and molecular insights emerged.
Conclusion: This is the largest nationwide study of the molecular genetics of childhood PAI un-
dertaken. Achieving a molecular diagnosis in more than 80% of children has important transla-
tional impact for counseling families, presymptomatic diagnosis, personalized treatment (eg, min-
eralocorticoid replacement), predicting comorbidities (eg, neurological, puberty/fertility), and
targeting clinical genetic testing in the future. (J Clin Endocrinol Metab 101: 284–292, 2016)
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Primary adrenal insufficiency (PAI) is a potentially life-threatening condition that requires accurate diagno-
sis and urgent treatment with glucocorticoid and often
mineralocorticoid replacement. Because the symptoms
and signs of adrenal insufficiency are often nonspecific,
the diagnosis may be easily overlooked (1).
In contrast to the predominance in autoimmune etiol-
ogies in adults, most causes of PAI in childhood have an
inherited, monogenic origin (1–3). Genetic causes of pe-
diatric PAI can be classified into four major groups
according to the underlying pathogenesis; 1) impaired ste-
roidogenesis, 2) adrenal hypoplasia, 3) familial glucocor-
ticoid deficiency (FGD) and FGD-like disorders, and 4)
adrenal destruction.
Congenital adrenal hyperplasia (CYP21A2, CYP11B1,
HSD3B2, CYP17A1, POR deficiencies) constitutes the
largest subgroup of impaired steroidogenesis and is the
most common cause of PAI in children (1, 2, 4). In con-
trast, there are other individually rare causes of PAI.
Several genetic causes of adrenal hypoplasia (NR0B1/dos-
age-sensitive sex reversal, adrenal hypoplasia congenita
critical region, on the X chromosome, gene 1 [DAX-1],
NR5A1/SF-1, CDKN1C gene defects), congenital lipoid
adrenal hyperplasia (CYP11A1, STAR gene defects), fa-
milial glucocorticoid deficiency (FGD) and FGD-like con-
ditions (MC2R [FGD1], MRAP [FGD2], STAR, MCM4,
NNT, TXNRD2 gene defects) and adrenal destruction
(AIRE, ABCD1, PEX1, LIPA gene defects) are now well
established (5–16). However, it is also emerging that there
is considerable overlap in the clinical and biochemical pre-
sentation of these conditions. For example, FGD/FGD-
like conditions (MC2R, MRAP, NNT gene defects) can
present with salt loss suggestive of adrenal hypoplasia, and
alterations in STAR and CYP11A1 resulting in partial loss
of protein function may have a predominant FGD-like
phenotype (17–20).
Establishing a specific genetic diagnosis of PAI is ex-
tremely valuable for identifying presymptomatic children
who could benefit from treatment before the onset of po-
tentially life-threatening symptoms and for counseling
family members appropriately about the risk of passing
the condition on to their children (1, 3, 20, 21). Knowing
the genetic etiology can also help to modify treatments,
such as the need for long-term mineralocorticoid replace-
ment, and can predict potential comorbidities, such as im-
paired puberty or fertility and neurological dysfunction.
Next-generation sequencing (NGS) approaches are
revolutionizing our ability to sequence large numbers of
genes quickly and cost effectively. In this study, a custom
panel-based NGS approach has been used to sequence all
known PAI-associated genes in a national cohort of 95
children with PAI of unknown etiology.
Patients and Methods
Patients
A pediatric cohort study was performed with PAI patients
recruited from 19 pediatric endocrinology clinics in Turkey. In-
clusion criteria of a PAI phenotype was defined as the presence
of signs and symptoms of adrenal insufficiency together with
high plasma ACTH and low serum cortisol and intermediary
glucocorticoid metabolites at initial presentation. Exclusion cri-
teria were as follows: 1) congenital adrenal hyperplasia (21-
hydroxylase, 11-hydroxylase, 3-hydroxysteroid dehydroge-
nase 2, 17-hydroxylase, or cytochrome P450 reductase
deficiencies) diagnosed by a distinctive serum steroid hormone
profiles; 2) X-linked adrenoleukodystrophy in boys with neuro-
logical findings and elevated very long-chain fatty acids, or a
family history of affected males with adrenoleukodystrophy; 3)
clinical and biochemical evidence of autoimmune adrenal fail-
ure; and 4) known syndromic causes of PAI (specifically, classic
Triple A syndrome or Xp deletion syndrome involving NR0B1/
DAX-1 with Duchenne muscular dystrophy) (Figure 1).
All patients were assessed by a pediatric endocrinologist. A
structured questionnaire was used to systematically evaluate all
clinical, biochemical, and imaging data related to the diagnosis
and treatment of PAI and all other relevant medical and family
history. Studies were performed with the approval of the Ethics
Committee of the Marmara University Faculty of Medicine
(Istanbul, Turkey; B.30.2.MAR.0.01.02/AEK/108). Patients
and/or parents provided written informed consent, and all stud-
ies were conducted in accordance with the principles of the Dec-
laration of Helsinki.
A total of 95 PAI patients (48 females and 47 males) from 85
families and their unaffected siblings and parents were included
(Figure 1). The most common presenting features were hyper-
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pigmentation (94%), salt-wasting crisis/electrolyte imbalance
(51%), hypoglycemia with/without convulsions (47%), vomit-
ing/abdominal pain (26%), prolonged jaundice (24%), fatigue
(18%), neonatal respiratory distress (17%), frequent infections
(11%), and failure to thrive or weight loss (7%). Seven patients
had 46,XY disorders of sex development (DSD). Detailed clinical
findings are provided in Supplemental Table 1.
Parents of patients were consanguineous in 63 (74%) fami-
lies, whereas 22 families did not report consanguinity. A total of
51 patients were on hydrocortisone treatment alone, whereas 44
were also commenced on mineralocorticoid replacement due to
salt wasting, high plasma renin activity, or low aldosterone.
Eight families had multiple affected siblings (six pairs, two trios,
n  18).
Molecular analyses
DNA samples
Genomic DNA was extracted from whole blood of patients,
parents, and available unaffected siblings using a QIAamp DNA
blood maxikit (QIAGEN Inc).
Design of targeted gene panel
A custom HaloPlex DNA target enrichment panel (Agilent
Technologies Inc) was designed (SureDesign) to capture 160
known and candidate genes involved in adrenal development
and function. All coding exons and 100 base pairs of intronic
flanking sequence were included. The panel covered known
genes potentially causing PAI, congenital adrenal hyperplasia-
related genes, potential syndrome-related genes and candidate
genes based on data from biochemical/biological pathways,
mouse models of adrenal dysfunction, and gene expression (Sup-
plemental Methods).
Sequence capture and NGS
Sequence capture was performed according to the HaloPlex
Target Enrichment Protocol version D.5 (Agilent Technologies
Inc) for Illumina sequencing (Supplemental Methods). Patient
genomic DNA aliquots (225 ng) were processed in batches of 24
samples at a time with an enrichment control DNA sample as a
positive control. Sequencing was performed on a MiSeq next-
generation sequencer (Illumina Inc).
Variant analysis
Sequence alignment and variant calling were performed using
SureCall (version 2.0) software (Agilent Technologies Inc). All
potential disease causing variants were confirmed by PCR and
Sanger sequencing. Variants in known disease genes were con-
sidered highly likely to be pathogenic if they segregated with the
phenotype with an appropriate inheritance pattern within fam-
ilies, were determined damaging or likely damaging by several
bioinformatic prediction models (Ensembl Variant Effector Pre-
dictor; SIFT; PolyPhen2; and Mutation Taster) and if they had
been reported previously. In addition, novel missense changes
were absent in at least 200 Turkish control samples and had a
Figure 1. Overview of the study design, recruitment, and outcome of genetic analysis. ALD, adrenoleukodystrophy.
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minor allele frequency less than 1:100 000 in the Exome Aggre-
gation Consortium (ExAC) browser (ExAC; Cambridge, MA,
http://exac.broadinstitute.org; accessed July 2015).
More detailed description of methods, workflows, coverage,
and quality control are provided in Supplemental Methods.
Results
A molecular genetic diagnosis was obtained in 81% chil-
dren with PAI (77 of 95) using this targeted NGS ap-
proach. A total of 43 different deleterious nonsynony-
Table 1. Sequence Variations Detected in Our Cohort of 95 Children With Primary Adrenal Insufficiency
Gene
(Chromosome)
Familial,
n
Sporadic,
n
Total,
n Variants n Consanguinity
Mineralocorticoid
Treatment
MC2R (18p11.21) 4 21 25 22/25 (88%) 2/25 (8%)
p.D103N 1
p.G116V 2
p.R137W 1
p.V142L 1
p.T143S 1
p.L225R 1
p.G226R 1
p.A233P 2
p.C251W 2
c.560delT (p.V187Afs*29) 10
Deletion 3
NR0B1 (Xp21.2)a 6b 6 12 3/12 (25%) 12/12 (100%)
p.W235* 3
p.W236* 1
p.E256* 3
p.W291C 1
p.L299R 1
p.Y378* 1
p.C396* 1
p.V269del 1
STAR (8p11.23) 2 9 11 8/11 (72%) 11/11 (100%)
p.S13P 3
p.W96C 2
p.L157P 1
p.E169K 1
p.R182H 1
p.W250*/p.I166M 1
p.S12Afs*9 1
p.K159del 1
CYP11A1 (15q24.1) 2 7 9 8/9 (89%) 6/9 (67%)
p.R451W 9
MRAP (21q22.11) 2 7 9 5/9 (56%) 2/9 (22%)
p.L53P 1
c.IVS3ds  1insT 1
c.IVS3ds  1delG 5
p.K30del 2
NNT (5p12) 2 5 7 7/7 (100%) 2/7 (29%)
p.D178G 1
p.H370R 1
c.1769dupA (p.D590Efs*29) 1
c.2396delC (p.P799Qfs*22) 1
c.127_128delTG (p.W43Vfs*2) 2
Deletion (exon 2–3) 1
ABCD1 (Xq28)a 0 2 2 0/2 1/2
p.G512S 1
p.Y547C 1
NR5A1 (9q33.1) 0 1 1 0/1 1/1
p.R92Q 1
AAAS (12q13.13) 0 1 1 1/1 0/1
p.R445* 1
Total 18 59 77 54/77 (70%) 37/77 (48%)
Novel variants are marked in bold. All mutations are homozygous except for hemizygous mutations in X-linked genes and p.W250*/p.I166M in
STAR which was compound heterozygous.
a Hemizygous mutations in X-linked genes.
b Familial cases included sibling pairs except for NR0B1 in which two sibling trios were identified. Nucleotide position of variants is shown in
Supplemental Table 1.
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mous variations were detected in nine different genes
(Table 1). These changes were all confirmed by Sanger
sequencing and included missense mutations (n  24),
nonsense mutations (n  7), frameshift mutations (n  5),
in-frame single codon deletions (n  3), splice site disrup-
tions (n  2), and whole gene/exon deletions (n  2). Of
these variations, 22 (51%) had not been reported previ-
ously but were considered to be causative because they
segregated with the phenotype in the family, they were
classed as damaging or probably damaging by several
bioinformatic predictions, and they were not found in the
control samples or databases (Supplemental Table 2). The
remaining 21 mutations have been reported (Supplemen-
tal Table 1). A molecular diagnosis was reached in all eight
families with multiple affected siblings, including novel
changes in five families (Table 1).
The range of genetic etiologies found in this cohort were
as follows: MC2R (n  25), NR0B1 (n  12), STAR (n 
11), CYP11A1 (n  9), MRAP (n  9), NNT (n  7),
ABCD1 (n  2), NR5A1 (n  1), and AAAS (n  1)
(Figure 2). Most patients were homozygous for recessive
changes (62 of 77, 80%), one patient carried compound
heterozygous changes (1 of 77, 1.3%), and 14 patients had
hemizygous mutations in X-linked genes (NR0B1,
ABCD1) (14 of 77, 18%). As expected, consanguinity
rates were much higher in families of patients harboring
mutations in recessive genes (51 of 63, 81%) compared
with X-linked genes (3 of 14, 21%; P  .0001) (Table 1).
Recurrent mutations were detected in several genes, such
as c.560delT in MC2R (10 patients from nine unrelated
families), p.R451W in CYP11A1 (nine patients from eight
unrelated families), c.IVS3ds1delG in MRAP (five pa-
tients from five unrelated families), and p.S13P in STAR
(three patients from two unrelated families). Geographical
hot spots were found for the p.R451W CYP11A1 muta-
tion in eastern Turkey and for the c.IVS3ds1delG MRAP
mutation in the west (Figure 3, A and B).
Although there was considerable overlap in the clinical
and biochemical features of children within this cohort
(Supplemental Table 1), several notable findings have
emerged. For example, most patients with MC2R, MRAP,
and STAR mutations presented in the first weeks or
months of life, whereas children with the p.R451W mu-
tation in CYP11A1 presented in early childhood (1–6 y)
(Figure 4). Children with nicotinamide nucleotide trans-
hydrogenase (NNT) changes presented at different ages in
the first 2 years, whereas boys with NR0B1 (DAX-1) mu-
tations had a bimodal pattern, presenting either in the first
month of life or else after 18 months.
Most children had extremely high ACTH levels at di-
agnosis and almost all children, even babies, were clini-
cally hyperpigmented. Hypoglycemia was a frequent find-
ing, and hypoglycemic convulsions at presentation were
more common in children with MC2R (22 of 25, 88%)
and MRAP (five of nine, 56%) mutations than in children
with an alternative diagnosis (5 of 43, 12%) (P  .0001).
Salt-wasting states requiring mineralocorticoid replace-
ment occurred in all children with NR0B1 (DAX-1) and
STAR mutations and in most children with the CYP11A1
p.R451W change (six of nine, 66%) (Table 1). Fewer chil-
dren with NNT (two of seven, 28%), MRAP (two of nine,
22%), and MC2R (2 of 25, 8%) mutations required min-
eralocorticoid replacement, although four additional
children with MC2R defects had transient hyponatremia
(sodium 117–133 mmol/L) that resolved without fludro-
cortisone treatment (Supplemental Table 1). Adrenal im-
aging was generally uninformative, showing normal sized
or hypoplastic glands for most of these diagnoses, includ-
ing many children with STAR mutations (congenital li-
poid adrenal hyperplasia) in which enlarged adrenals are
reported (22).
Additional clinical features were seen in many children
in this cohort, such as altered growth, neuromotor delay,
learning difficulties, and cardiac defects (Supplemental
Table 1). Abnormalities in thyroid function such as sub-
clinical hypothyroidism were common (n  20, 26%),
whereas thyroglossal cysts (n  2), primary hypothyroid-
ism (n  2), and transient hypothyroidism (n  1) were
also found. DSD occurred in all six 46,XY infants with
STAR mutations. Five of these children were phenotypic
females who presented with a salt-losing crisis, and in two
cases a karyotype was not available prior to this genetic
analysis. The one boy with severe hypospadias due to
STAR deficiency developed hypergonadotropic hypogo-
nadism in puberty and needed T replacement. One of the
four boys with the p.R451W mutation in CYP11A1 had a
small penis and cryptorchidism. One boy with a NR0B1
mutationandX-linkedadrenalhypoplasia congenita (AHC)
had macrophallia and another one had cryptorchidism. Co-
incidental hypospadias and unilateral cryptorchidism was
found in one boy with disruption of MC2R.
Figure 2. Pie chart showing the percentage of mutations in each
gene in this cohort of children with PAI.
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Stature was variable in the 25 children with MC2R
mutations with seven children (28%) having tall stature
(2 SD score or two percentile lines above parental target
height), four having short stature (2 SD score) and the
rest being within the normal range. There was no history
of preterm birth associated with CYP11A1 mutations, but
there were reports of multiple stillbirths in three families
in which a child had severe disruption of MC2R (deletion
or c.560delT frameshift). Despite the range of neurolog-
ical and other features seen, the two boys with mutations
in ABCD1 (causing X-linked adrenoleukodystrophy) and
one boy with disruption of AAAS (causing Triple A syn-
drome) appeared to have adrenal only phenotypes and
would not have been diagnosed without genetic testing.
Discussion
The past 20 years has seen significant progress in our under-
standing of the genetic causes of childhood PAI. However, it
is unclear how much these genes con-
tribute to pediatric adrenal disease in
theclinicalsettingasmostreportshave
focused on specific categories of adre-
nal disease such as FGD or adrenal hy-
poplasia (6, 9).
In this study, an unbiased nation-
wide cohort of almost 100 children
with PAI was recruited from 19 pedi-
atric endocrinology centers across
Turkey, and a molecular diagnosis
was reached in more than 80% of the
children. This represents the largest
clinical cohort of children with this
rare condition assembled. Because
children could die from convulsions,
respiratory distress, or salt-losing cri-
ses before reaching the hospital or get
misdiagnosed with sepsis, the condi-
tion may be underdiagnosed. In fact, a
history of unexplained death in in-
fancy or childhood in the extended
family was common in many of those
questioned.
Targeted panel-based capture and
high-throughput sequencing proved
very effective in reaching a molecular
diagnosis in a relatively quick and
comprehensive manner. A total of 43
known and novel mutations in nine
genes were discovered in 77 patients,
with 73 of 77 mutations (95%) oc-
curring in six genes (MC2R, NR0B1,
STAR, CYP11A1, MRAP, and NNT). Several recurrent
mutations were discovered, which likely represent
founder effects. Some of these are localized to certain geo-
graphical areas (eg, p.R451W in CYP11A1 in eastern Tur-
key, c.IVS3ds1delG inMRAP inwesternTurkey),which
could lead to focused cost-effective clinical genetic testing
for patients and families at risk of adrenal insufficiency in
these regions (Figure 3A). Other recurrent changes, such
as the c.560delT in MC2R showed more diverse geograph-
ical distribution across the country, possibly reflecting mi-
gration toward the west (Figure 3B). Indeed, this MC2R
mutation has been reported previously in the father of two
siblings with FGD1 who originated from northern Iran,
close to the Turkish border (17). Sanger sequencing for
just the three changes in MC2R, CYP11A1, and MRAP
would have diagnosed 22 of 85 different families recruited
in this nationwide cohort (26%), which could represent a
cost-effective approach to first-line clinical genetic anal-
ysis. Of note, no mutations were found in MCM4 or
Figure 3. Geographical distribution of recurrent mutations identified in this study. A, The MRAP
c.IVS3ds1delG mutation was identified mainly in patients from west Turkey, whereas the
CYP11A1 p.R451W mutation was found in patients who originated from east Turkey. The first
report of the CYP11A1 p.R451W mutation was in a family from Germany who were originally
from Elazig (shown in light pink) (20). B, The MC2R c.560delT mutation showed a wider
distribution most likely reflecting migration from the east to west of Turkey and has been
described previously in a family from northern Iran (17).
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TXNRD2, which to date have been described only in Irish
Traveler and Kashmiri families, respectively (12, 14, 23)
In addition to defining the population genetics of PAI,
this study has provided some useful clinical and novel mo-
lecular insight into several of these specific conditions.
Mutations in MC2R (encoding the ACTH receptor) are
well established as the cause of FGD1, and approximately
40 different missense changes have been reported (9).
Children typically present with hypoglycemia or hyper-
pigmentation in early infancy or in childhood, but com-
plete lossof functionmutationsare rare (17,24).Although
diverse missense mutations were common in our cohort,
severely disruptive changes in MC2R were found in more
than half of the children (13 of 25), all of whom presented
in the first 6monthsof lifewithhypoglycemic convulsions,
respiratory distress, or both. In addition to the c.560delT
mutation discussed above, the first complete deletions of
the MC2R locus were found in three patients. Although
ACTH plays a facilitative role in supporting mineralocor-
ticoid release, children with FGD1 do not typically have
salt loss. However, transient hyponatremia has been re-
ported in several children with severe disruption of the
receptor, sometimes leading to a misdiagnosis of adrenal
hypoplasia (17, 25). Similar observations were seen in this
cohort, with 5 of 25 children having evidence of hypona-
tremia (sodium 117–133 mmol/L) but only two of them
receiving long-term fludrocortisone replacement. On the
basis of the genetic diagnosis, it is likely the need for this
treatment can be reviewed. The significance of recurrent
stillbirths in three families with severe loss of MC2R func-
tion is unclear. Although tall stature at diagnosis has been
suggested for MC2R mutations, any effects on growth are
difficult to interpret because most of our cohort were di-
agnosed and treated in infancy (26).
Hemizygous mutations in NR0B1 (encoding the nu-
clear receptor DAX-1) were found in 12 boys, including in
two families in which three sons were affected. Mutations
in NR0B1 cause X-linked AHC and more than 100 dif-
ferent mutations are reported (5). Most are frameshift or
nonsense mutations that disrupt protein function, with a
clustering of missense changes in three regions of the li-
gand-like binding domain (27). The three missense
changes identified here (p.V269del, p.W291C, p.L299R)
are located in a loop region of helix 3 to helix 5 that in-
teracts with NR5A nuclear receptors (such as steroido-
genic factor-1) (28). The novel p.L299 lies adjacent to the
frequently mutated p.A300 residue, whereas codons
p.V269 and p.W291 have been mutated previously in non-
Turkish pedigree (5). All DAX-1-deficient boys presented
with salt loss and showed a bimodal distribution pattern
of age at presentation as reported previously (Figure 4)
(29). Although currently preadolescent, they are likely to
develop hypogonadotropic hypogonadism and infertility
as part of their condition, so establishing the diagnosis in
childhood will help plan endocrine management of pu-
berty, counseling, and potential assisted reproduction
(30). Macrophallia in infancy, found in one boy, is emerg-
ing as a rare feature of X-linked AHC (31).
True CYP11A1 deficiency (encoding P450 side chain
cleavage [P450scc]) is a relatively recently established
endocrine condition because it was thought that disrup-
tion of this enzyme, which facilitates the first three steps in
conversion of cholesterol to pregnenolone, would be in-
compatible with fetal survival in humans (4). However,
several children with this condition are now reported (32,
33). Severe loss of CYP11A1/P450scc function is usually
associated with severe salt-losing adrenal failure in the
neonatal period and a female phenotype in 46,XY children
(46,XY DSD). Milder changes can present later with ad-
renal insufficiency and a history of hypospadias in boys
(34, 35). The p.R451W variant found in all our patients
was described recently in two brothers of Turkish origin
residing in Germany who had normal genitalia and child-
hood-onset PAI (20). Their family originated from the
Elazig region of Eastern Anatolia, a province bordering
two regions where our patients lived (Figure 3A). The
p.R451W mutation disrupts hydrogen bonds with resi-
dues F428 and Y449 in the K-L loop of the enzyme, caus-
ing partial loss of function consistent with the late pre-
sentation and normal genitalia in three of the four boys
(20). Nevertheless, all children will need careful follow-up
through puberty and into adult life to monitor sex hor-
mone production and fertility. These findings confirm that
mild loss of CYP11A1/P450scc function can present with
isolated adrenal insufficiency and normal male genitalia,
similar to mild loss of function of STAR (18–20).
Figure 4. Age at presentation of the patients with PAI.
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Defects in STAR (encoding steroidogenic acute regu-
latory protein) disrupt the transport of cholesterol into
mitochondria and classically lead to congenital lipoid ad-
renal hyperplasia (4, 22). A range of mutations were
found, including recurrent p.S13P changes in three pa-
tients including two siblings. This is by far the most ami-
noterminal STAR mutation reported to date and affects
the mitochondrial leader that is involved in targeting and
localizing STAR to the outer mitochondrial membrane
(36). Classic congenital lipoid adrenal hyperplasia is as-
sociated with severe salt-losing adrenal failure and 46,XY
DSD due to a block in both adrenal and testicular steroid-
ogenesis. The two-hit hypothesis suggests that after an
initial reduction in steroid production and increased
ACTH drive, accumulation of intracellular lipid has a sec-
ondary toxic effect on cells (22). Interestingly, nine of the
children presented between 3 weeks and 3 months of age,
consistent with the two-hit hypothesis, whereas only two
presented in the first week (22). Two girls were found to
have 46,XY DSD only after genetic analysis revealed
STAR deficiency, highlighting the importance of obtain-
ing a karyotype in phenotypic girls with salt-losing adrenal
failure. As with CYP11A1/P450scc deficiency, these chil-
dren all need endocrine follow-up for life to monitor pu-
berty and ovarian function in 46,XX girls and for puberty
induction and sex steroid replacement in 46,XY DSD. In-
deed, the one patient with hypospadias raised male is now
showing evidence of hypergonadotropic hypogonadism in
adolescence.
Mutations in MRAP (encoding melanocortin 2 recep-
tor-associated protein) and NNT (encoding nicotinamide
nucleotide transhydrogenase) cause adrenal insufficiency
without other features and can only be diagnosed by ge-
netic analysis, as shown here. MRAP is essential for traf-
ficking the ACTH receptor (melanocortin 2 receptor) to
the cell membrane, and mutations causing FGD2 were
first described in 2005 (9, 10, 24). The intron 3 splice site
is especially vulnerable, often resulting in early-onset ad-
renal insufficiency. Patients with novel aminoterminal
point mutations (p.K30del, p.L53P) presented unusually
late (3.5–13 y) (Figure 4), consistent with reports of chil-
dren with p.V26A and p.Y59D changes (37).
NNT mutations affect cellular oxidation and were
first decribed in 2012; approximately 20 children have
been reported to date (9, 13, 38). The six novel changes
found here include familial homozygous deletions of
exons 2–3 and homozygous missense mutations in the
mitochondrial matrix region (p.D178G, p.H370R).
These findings confirm the importance of NNT for ad-
renal function in an independent cohort. Unlike in other
studies, compound heterozygous mutations were not
found (13).
Heterozygous mutations in NR5A1 (encoding the nu-
clear receptor steroidogenic factor-1) usually cause 46,XY
DSD or primary ovarian insufficiency (5). Adrenal insuf-
ficiency is extremely rare and has been reported only once,
in a 46,XX girl (39). The homozygous p.R92Q mutation
found here in a 46,XX girl with early-onset PAI is fasci-
nating because the same homozygous change was reported
in a 46,XY phenotypic female with adrenal failure from
central Turkey in 2002 (40). This finding reinforces the
importance of the A-box motif of steroidogenic factor 1 in
monomeric binding to DNA and provides conclusive ev-
idence that severe disruption of steroidogenic factor 1 can
cause adrenal insufficiency in humans.
Finally, mutations identified in AAAS (typically caus-
ing Triple A syndrome: achalasia, alacrima, Addison dis-
ease) and ABCD1 (typically causing X-linked adrenoleu-
kodystrophy) in three children without other features
shows how genetic screening can identify adrenal-only
phenotypes in young people who may be at risk of devel-
oping other symptoms in later life (11, 15).
This nationwide cohort study of high-throughput ge-
netic screening of children with rare causes of PAI has
provided many novel and supportive clinical and molec-
ular insights and has significant impact on the manage-
ment of these patients and their families. New genetic tech-
nologies are a powerful tool in defining population
genetics of rare conditions and will allow more focused
clinical genetic screening programs to be established.
Acknowledgments
We thank the Exome Aggregation Consortium and the groups
that provided exome variant data for comparison. A full list of
contributing groups can be found at http://exac.broadinstitute.
org/about.
Address all correspondence and requests for reprints to: Tu-
lay Guran, MD, Department of Pediatric Endocrinology and
Diabetes, Marmara University, Fevzi Cakmak Mh. Mimar Sinan
Cd. No 41, 34899 Ustkaynarca/Pendik, Istanbul, Turkey.
E-mail: tulayguran@yahoo.com.
This work was supported by Turkish Pediatric Endocrinol-
ogy Research Grant UPE-2014-2. J.C.A. is a Wellcome Trust
Senior Research Fellow in Clinical Science (Grant 098513/Z/12/
Z), with support from the National Institute for Health Research
Biomedical Research Centre at Great Ormond Street Hospital
for Children NHS Foundation Trust and University College Lon-
don. T.G. is a European Community, Marie-Curie research fel-
low (Grant PIEF-GA-2012-328959).
Disclosure Summary: The authors have nothing to disclose.
References
1. Hsieh S, White PC. Presentation of primary adrenal insufficiency in
childhood. J Clin Endocrinol Metab. 2011;96:E925–E928.
doi: 10.1210/jc.2015-3250 press.endocrine.org/journal/jcem 291
D
ow
nloaded from
 https://academ
ic.oup.com
/jcem
/article-abstract/101/1/284/2806864 by Pam
ukkale U
niversity user on 29 June 2020
2. Perry R, Kecha O, Paquette J, Huot C, Van Vliet G, Deal C. Primary
adrenal insufficiency in children: twenty years‘ experience at the
Sainte-Justine Hospital, Montreal. J Clin Endocrinol Metab. 2005;
90:3243–3250.
3. Malikova J, Flück CE. Novel insight into etiology, diagnosis and
management of primary adrenal insufficiency. Horm Res Paediatr.
2014;82:145–157.
4. Miller WL, Auchus RJ. The molecular biology, biochemistry, and
physiology of human steroidogenesis and its disorders. Endocr Rev.
2011;32:81–151.
5. Suntharalingham JP, Buonocore F, Duncan AJ, Achermann JC.
DAX-1 (NR0B1) and steroidogenic factor-1 (SF-1, NR5A1) in hu-
man disease. Best Pract Res Clin Endocrinol Metab. 2015;29:607–
619.
6. Lin L, Gu WX, Ozisik G, et al. Analysis of DAX1 (NR0B1) and
steroidogenic factor-1 (NR5A1) in children and adults with primary
adrenal failure: ten years’ experience. J Clin Endocrinol Metab.
2006;91:3048–3054.
7. Arboleda VA, Lee H, Parnaik R, et al. Mutations in the PCNA-
binding domain of CDKN1C cause IMAGe syndrome. Nat Genet.
2012;44:788–792.
8. Meimaridou E, Hughes CR, Kowalczyk J, Chan LF, Clark AJ,
Metherell LA. ACTH resistance: genes and mechanisms. Endocr
Dev. 2013;24:57–66.
9. Meimaridou E, Hughes CR, Kowalczyk J, et al. Familial glucocor-
ticoid deficiency: New genes and mechanisms. Mol Cell Endocrinol.
2013;371:195–200.
10. Metherell LA, Chapple JP, Cooray S, et al. Mutations in MRAP, en-
coding a new interacting partner of the ACTH receptor, cause familial
glucocorticoid deficiency type 2. Nat Genet. 2005;37:166–170.
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